Search clinical trials for: Interferon Inducers

Total 3937 results

Merck KGaA, Darmstadt, Germany
Merck spol.s.r.o., Czech Republic

Completed

Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® (SKORE)

Multiple Sclerosis, Relapsing-Remitting

Czech Republic
Mongolian National University of Medical Sciences
Mongolian National Cancer Center

Recruiting

Interferon Alpha Therapy for Cervical CINI and HPV Infection

HPV Infection | Cervical Dysplasia

Mongolia
Beijing Ditan Hospital

Completed

Cohort Study of Efficacy and Safety of Interferon Intermittent Treatment of Chronic Hepatitis B

Chronic Hepatitis B

China
Pontificia Universidad Catolica de Chile
Altum Pharmaceuticals INC

Completed

Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19) (IN2COVID)

Coronavirus Disease 2019

Chile
Fudan University

Withdrawn

The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma
The University of Hong Kong

Completed

Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC

Hepatocellular Carcinoma
Pusan National University Hospital

Unknown

HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance

Chronic Hepatitis B

Korea, Republic of
Biogen

Completed

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (PLENO)

Relapsing Remitting Multiple Sclerosis

Portugal
InterMune

Completed

CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)

Chronic Hepatitis C

United States
Kadmon Corporation, LLC

Withdrawn

Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C (REACHSVR)

Hepatitis C
Cinnagen

Completed

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis (RRMS)

Iran, Islamic Republic of
Biogen

Completed

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

Germany
IRCCS Eugenio Medea

Completed

Open Trail of γIFN for Friedreich Ataxia

Friedreich Ataxia
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa in Treating Patients With Advanced Kidney Cancer

Kidney Cancer

United States
National Center for Research Resources (NCRR)
Tulane University School of Medicine

Completed

Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C

Hepatitis C
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
CytoPharm, Inc.

Completed

Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C

Hepatitis C, Chronic

Taiwan
Lymphoma Study Association

Unknown

Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Lymphoma

United Kingdom, France
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma

Lymphoma | Small Intestine Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa

Melanoma (Skin)

United States
University of Turin, Italy
Dimensione Ricerca s.r.l.

Completed

Optimizing IFN Beta - 1B Dose (Optims)

Multiple Sclerosis
Interferon Sciences

Completed

Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects

HIV Infections

United States
Beijing Ditan Hospital

Unknown

Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention

Chronic Hepatitis B Infection

China
Turku University Hospital

Unknown

Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial (Hypogamma Int1)

Rhinovirus Infection

Finland
Biogen

Completed

Open-Label Safety Extension Study of Avonex

Multiple Sclerosis
Biogen

Completed

Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers

Multiple Sclerosis
University of Utah

Recruiting

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis (ATIOM)

Myelofibrosis

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Sunnybrook Health Sciences Centre

Completed

Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon

Follicular Lymphoma

Canada
Bayer

Completed

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment (BEACON)

Relapsing Remitting Multiple Sclerosis (RRMS)

China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
National Institute of Allergy and Infectious Diseases...
Hoffmann-La Roche

Completed

Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.

HIV Infections | Anus Neoplasms

United States
Peking University People's Hospital

Unknown

Interferon α for the Therapy of Minimal Residual Disease

Leukemia

China
S. Andrea Hospital

Unknown

Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients

Multiple Sclerosis

Italy
EMD Serono
Pfizer

Completed

RNF and Betaseron® Tolerability Study (REFORMS)

Relapsing Remitting Multiple Sclerosis (RRMS)

United States
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Essential Thrombocytopenia

China
Biocad

Completed

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Healthy

Russian Federation
Minneapolis Veterans Affairs Medical Center
US Department of Veterans Affairs; Kadmon Corporation, LLC; InterMune; San Diego... and other collaborators

Completed

Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial

Chronic Hepatitis C
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Melinda Magyari
University of Copenhagen

Completed

REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients (REPAIR)

Multiple Sclerosis
Wake Forest University Health Sciences
American College of Gastroenterology

Completed

Intravenous Interferon During Liver Transplant

Hepatitis C | Cirrhosis
Synairgen Research Ltd.

Completed

A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Bayer

Completed

China Betaferon Adherence, Coping and Nurse Support Study

Multiple Sclerosis, Chronic Progressive

China
Bayer

Completed

Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period (SEPLUS)

Multiple Sclerosis

France
Rutgers, The State University of New Jersey
Bayer

Completed

Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis

Multiple Sclerosis

United States
Biogen

Completed

A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers

Healthy

United States
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone (RETURN)

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone (REMAIN)

Multiple Sclerosis, Relapsing-Remitting
Bayer

Completed

Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis (BREAK)

Multiple Sclerosis

Poland
Bayer

Completed

Physical Activity and Fatigue in Early Multiple Sclerosis (MS) (BEGIN)

Multiple Sclerosis

Switzerland, France, Germany, Indonesia, Korea, Republic of, Spain, Sweden, Thailand, Taiwan, Australia, Austria, Colombia, Czech Republic, Italy, Jordan, Kazakhstan, Lebanon, Mexico, Slovenia, United Kingdom, Bahrain, Egypt, United... and more
Bayer

Completed

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

Multiple Sclerosis

Canada, United States
Cinnagen

Completed

Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)

Healthy | Bioequivalence

Finland

3

Subscribe